An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2019
Price : $35 *
At a glance
- Drugs JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Vaccines and Prevention B.V
- 04 Dec 2018 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Planned End Date changed from 30 Oct 2018 to 30 Nov 2018.
- 16 Aug 2018 Status changed from recruiting to active, no longer recruiting.